ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Cascade Therapy of Periodontitis via Sequential Release of Ribosome-Targeting Antimicrobial Peptide and Irisin From a Multifunctional MOF-Based System.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Surgical removal of bacterial plaque and antibiotic therapy have been widely used for the clinical treatment of periodontitis, which is driven by microbial dysbiosis and usually causes the loss of alveolar bone. However, key restrictions including drug resistance, poor anti-inflammatory effects, and limited bone repair capacity exist in antibiotic therapy, presenting challenges for periodontitis treatment. Consequently, it is urgently required to develop novel systems to combat antimicrobial resistance and enhance bone regeneration ability. Here, a MOF-based multicomponent system is developed, containing a cationic antimicrobial peptide GF for antimicrobial purpose and the adipomyokine Irisin for anti-inflammation, antioxidation, and promoting bone regeneration. The obtained composite Irisin/GF@NH
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.